Roche acquires innovatis AG to complement its product portfolio
- Details
- Category: Roche
Roche has signed a definite agreement under which Roche will acquire 100% of innovatis, a privately held company based in Bielefeld, Germany. innovatis is a leading provider of automated cell analysis solutions, especially focussing on cell counting, viability testing, and cell function analysis in research, as well as bioproduction. The purchase price for this transaction is 15 million Euros.
The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent
- Details
- Category: Abbott
A comprehensive analysis published today in The Lancet, one of the world's leading medical journals, from the ABSORB clinical trial demonstrated that Abbott's bioabsorbable drug eluting stent, currently in development, successfully treated coronary artery disease and was absorbed into the walls of treated arteries within two years.
Sanofi-aventis invests â¬100 million in new facility in Mexico
- Details
- Category: Sanofi
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY), has announced the signing of an agreement with the Mexican authorities to build a € 100 million facility to manufacture influenza vaccine in Mexico. The announcement was made during a ceremony attended by Felipe Calderon, President of Mexico, and Nicolas Sarkozy, President of France, who was in Mexico City for a State visit.
Roche Annual General Meeting: dividend raised by 9 percent
- Details
- Category: Roche
Roche's Annual General Meeting has approved all the Board of Directors' proposals. The 703 shareholders in attendance, representing 144,334,099, or 90.2% of a total of 160,000,000 bearer shares, approved the 2008 Annual Report and financial statements. They also authorised a +9% increase in the dividend to 5.00 Swiss francs per share and non-voting equity.
Merck and Schering-Plough to Merge
- Details
- Category: Merck
Merck & Co., Inc. (NYSE: MRK) and Schering-Plough Corporation (NYSE: SGP) announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Under the terms of the agreement, Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough.
Roche increases offer price for Genentech shares to US$ 93 per share
- Details
- Category: Roche
Roche (SWX: ROG.VX; RO.S) has increased its offer price for all outstanding publicly-held shares of Genentech (NYSE: DNA) to US$ 93 per share and extended the offer to 12:00 midnight, New York City time, on Friday, March 20, 2009. All other terms and conditions of the tender offer remain unchanged.
Lundbeck meets all of its financial forecasts for 2008 and expects continuing growth in 2009
- Details
- Category: Lundbeck
Lundbeck has presented annual accounts in which all of the financial results meet the financial guidance announced by the company in March 2008. For the first time ever, revenue exceeded DKK 11 billion in 2008, and Lundbeck's management considers the results highly satisfactory.
More Pharma News ...
- New diagnostic tool for Hypoactive Sexual Desire Disorder (HSDD) in women
- Pfizer Expands Portfolio of Generic Medicines in the U.S. and Europe
- AstraZeneca and MAP Pharmaceuticals, Inc. Announce Worldwide Collaboration
- Advances in Renal Cancer Journalists' Award
- Novartis shareholders approved 25% dividend increase
- Abbott Successfully Completes Tender Offer for Shares of Advanced Medical Optics
- Pfizer Discontinues Development of Two Phase 3 Compounds